cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Curious about the latest breakthrough

If youre considering any GLP-1 medication, start with a clinician who understands the science, not marketing hype

Clinical trials demonstrated average weight loss of 14.9 percent of body weight with the 2.4 mg maintenance dose over 68 weeks

These compounds differ in how they work, what they target, how long they stay active in the body, and what evidence exists to support their use

Are liquid calories creeping in

Users report the benefits feel natural at this point, the new normal rather than something actively noticed

Therefore, it is not a question of whether tirzepatide can activate the mGIPR, but rather what doses of tirzepatide are required to do so